Obesity drug demand already outstrips supply, so efficacy is no longer the constraint. The next competitive line runs through funded access: whether an employer or payer covers the drug, whether a prescription clears authorisation, and whether a patient stays on treatment long enough to keep the weight off. Lilly and Novo Nordisk are now building for that funnel, not just for the trial.
Why is the obesity market now about the funnel, not the molecule?
Clinical trial results made the obesity category. They no longer decide who wins it. A patient who is clinically eligible for a GLP-1 or dual incretin therapy still has to be funded by an employer plan or payer, get that prescription authorised, actually start the drug, and stay on it long enough for the outcome the trial promised to show up in their own life. Each of those stages loses people, and the loss compounds.
That is a different competitive problem than the one companies spent the last five years solving. A molecule that clears every one of those stages more reliably than a rival, even without a materially better efficacy number, can still win more of the market that actually gets treated. The companies that are building for the whole funnel, not just the headline trial result, are the ones setting the pace now.
This is also why the obesity category increasingly gets discussed in terms of access architecture rather than pipeline depth. The molecule got a company into the conversation. What happens after the prescription is written is what decides how much of the addressable population actually converts into a treated, adherent patient.
- 01
Confirm funded eligibility
Map which employers, plans and PBMs actually fund the drug for the target population.
- 02
Secure authorisation
Design the prior-authorisation path so eligible patients convert rather than stall.
- 03
Support initiation
Build the onboarding and telehealth pathway that gets a funded patient started.
- 04
Sustain persistence
Invest in the adherence support that keeps a started patient on treatment past month three.
What is replacing the efficacy ceiling?
For several years, the ceiling on the obesity market was clinical: how much weight a drug could help a patient lose, and how safely. That ceiling has not disappeared, but it is no longer the binding constraint for the leading therapies. The binding constraint now is an access ceiling: how many clinically eligible patients can actually get funded, authorised and started, and how many of those stay on treatment rather than discontinuing within the first year.
That shift changes what a company has to build. A market access team scoping employer and payer research for an obesity asset today is not just testing a value story against a cost-per-QALY threshold. It is mapping which employers, health plans, pharmacy benefit managers and telehealth channels actually convert eligible patients into funded, persistent ones, and building the account strategy around that funnel rather than around the trial data alone.
The practical effect is that obesity drugs are becoming a market of choice architecture. Formulary placement, prior-authorisation criteria, employer benefit design and persistence support programmes now do as much to decide market share as the underlying molecule does.
What are Lilly and Novo Nordisk building for?
Eli Lilly has been explicit about building access architecture rather than simply marketing a molecule. The company's Employer Connect initiative, announced in March 2026, is aimed directly at the funded-patient problem: getting employers to structure obesity-drug coverage in a way that gets eligible employees authorised and started, rather than leaving access to a fragmented, plan-by-plan prior-authorisation process that loses patients at every step.
Novo Nordisk is defending a franchise in a market that has become more segmented since its early lead. In August 2026, chief executive Mike Doustdar described the obesity opportunity in terms that put employer and payer access, not just molecule performance, at the centre of the company's strategy. The company's task is less about proving its therapy works and more about defending its share of a funded-patient pool that Lilly and others are now actively trying to grow and capture.
The parallel is worth noting: the same treatment-preference logic reshaping which therapy an account actually adopts is playing out in multiple sclerosis too, where route of administration and care-model fit are displacing efficacy as the deciding factor once several therapies clear a high clinical bar.
| US employer/payer market | EU / HTA market | |
|---|---|---|
| Gatekeeper | Employers, health plans, PBMs | National HTA or reimbursement body |
| Decision structure | Fragmented, account by account | Centralised, one population-wide verdict |
| Consequence of a gap | Lost access at individual employers | Access denied across the whole market |
How do US and EU gatekeepers differ for obesity drugs?
In the US, the gatekeepers are employers, health plans, pharmacy benefit managers and, increasingly, telehealth platforms that route patients into treatment outside the traditional primary-care visit. Coverage decisions are fragmented across thousands of individual plan sponsors, so a company's access strategy has to work account by account, employer by employer, rather than against a single national verdict.
In the EU and other single-payer or HTA-governed markets, the gatekeeper is more often a national body weighing cost-effectiveness and budget impact for the whole population at once. A favourable national reimbursement decision does more work in one motion than winning dozens of individual US employers, but it also means a single unfavourable verdict can close off an entire market rather than just one account.
For a company sequencing launches across both geographies, that difference matters more than it might for a conventional therapy, because the funded-patient funnel itself looks structurally different on each side of the comparison. A US employer strategy and an EU HTA dossier are not two versions of the same argument. They are two different funnels that happen to lead to the same molecule.
What should emerging obesity-drug companies plan for?
For a smaller company with a promising asset, whether an oral incretin from a developer such as Structure Therapeutics, an injectable from Viking Therapeutics, or another next-generation entrant, efficacy data alone is not going to be enough to win share from Lilly and Novo Nordisk. The companies building durable positions are the ones that can show a credible path through the funded-patient funnel: who pays, how authorisation works, and what keeps a patient on treatment past the first few months.
Oral formulations carry a specific access argument worth watching closely, since a pill removes some of the friction that depresses persistence with an injectable, particularly in employer and telehealth-driven US channels where patients self-manage adherence with less clinical support than a specialist-run programme provides.
The practical planning question is not whether the molecule works. It is whether the company can describe, concretely, how an eligible patient in a target market gets from diagnosis to a year of funded, persistent treatment, and what breaks that chain today. Building an access strategy on that question, well before launch, is what is separating the obesity category's winners from its also-rans.